PharmaCyte Biotech (PMCB) Competitors $1.74 -0.02 (-0.85%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends PMCB vs. ITRM, ICCC, IMRX, ANEB, OTLK, NBRV, PDSB, IMMX, ELYM, and RVPHShould you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include Iterum Therapeutics (ITRM), ImmuCell (ICCC), Immuneering (IMRX), Anebulo Pharmaceuticals (ANEB), Outlook Therapeutics (OTLK), Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Eliem Therapeutics (ELYM), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. PharmaCyte Biotech vs. Iterum Therapeutics ImmuCell Immuneering Anebulo Pharmaceuticals Outlook Therapeutics Nabriva Therapeutics PDS Biotechnology Immix Biopharma Eliem Therapeutics Reviva Pharmaceuticals Iterum Therapeutics (NASDAQ:ITRM) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation. Does the media favor ITRM or PMCB? In the previous week, Iterum Therapeutics had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 3 mentions for Iterum Therapeutics and 2 mentions for PharmaCyte Biotech. Iterum Therapeutics' average media sentiment score of 1.32 beat PharmaCyte Biotech's score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Positive PharmaCyte Biotech Neutral Do institutionals and insiders believe in ITRM or PMCB? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor ITRM or PMCB? Iterum Therapeutics received 141 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% PharmaCyte BiotechN/AN/A Which has better earnings and valuation, ITRM or PMCB? Iterum Therapeutics is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$1.31-1.06PharmaCyte BiotechN/AN/A$330K$0.533.29 Do analysts rate ITRM or PMCB? Iterum Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 261.01%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than PharmaCyte Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ITRM or PMCB? Iterum Therapeutics has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Is ITRM or PMCB more profitable? PharmaCyte Biotech's return on equity of 0.76% beat Iterum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -90.85% PharmaCyte Biotech N/A 0.76%0.45% SummaryIterum Therapeutics beats PharmaCyte Biotech on 8 of the 14 factors compared between the two stocks. Remove Ads Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricPharmaCyte BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.16M$3.06B$5.63B$8.06BDividend YieldN/A1.47%4.89%4.04%P/E Ratio3.2927.7123.7918.96Price / SalesN/A369.31381.68117.09Price / CashN/A168.6838.0534.62Price / Book0.533.446.874.23Net Income$330,000.00-$71.72M$3.19B$246.59M7 Day Performance-2.51%-2.98%-2.50%-3.09%1 Month Performance8.39%-9.70%-7.40%-8.97%1 Year Performance-11.42%-23.02%8.97%1.27% PharmaCyte Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBPharmaCyte Biotech0.9631 of 5 stars$1.75-0.9%N/A-12.4%$12.16MN/A3.294Upcoming EarningsShort Interest ↓ITRMIterum Therapeutics1.7905 of 5 stars$1.33-4.7%$5.00+275.9%-17.3%$45.99MN/A-1.0210Positive NewsICCCImmuCell0.4135 of 5 stars$5.16-2.3%N/A-7.5%$45.99M$26.49M-10.3270Positive NewsGap UpIMRXImmuneering3.336 of 5 stars$1.48-10.3%$12.20+724.3%-74.7%$45.95M$320,000.00-0.7560ANEBAnebulo Pharmaceuticals3.4584 of 5 stars$1.11-4.3%$8.00+620.7%-49.8%$45.60MN/A-3.964Positive NewsGap DownOTLKOutlook Therapeutics1.8039 of 5 stars$1.42-5.3%$10.20+618.3%-80.8%$45.46MN/A-0.1920Positive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070Analyst ForecastNews CoveragePDSBPDS Biotechnology1.6933 of 5 stars$1.21-9.0%$11.67+864.2%-75.6%$45.27MN/A-1.0420IMMXImmix Biopharma2.8485 of 5 stars$1.62-9.0%$7.00+332.1%-46.8%$44.56MN/A-1.919Positive NewsELYMEliem TherapeuticsN/A$1.45+4.3%N/A-49.7%$43.14MN/A-2.749Gap DownRVPHReviva Pharmaceuticals4.0885 of 5 stars$1.28-11.1%$11.40+790.6%-65.1%$42.80MN/A-1.155 Remove Ads Related Companies and Tools Related Companies ITRM Competitors ICCC Competitors IMRX Competitors ANEB Competitors OTLK Competitors NBRV Competitors PDSB Competitors IMMX Competitors ELYM Competitors RVPH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMCB) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMCB Stock Alerts